Hanmi Reports Early Phase 1 Cancer Drug Safety Data
Hanmi Pharmaceutical's two experimental cancer candidates, HM97662 and BH3120, showed favorable safety and early anti-tumor activity in Phase 1 trials.
Updated on Nov. 17, 2026 in Cancer

Hanmi Pharmaceutical confirmed initial anti-tumor activity and a favorable safety profile for its Phase 1 candidates HM97662 and BH3120. The company presented the results in a poster at ESMO Congress 2026 in Madrid.
Why it matters
Early-stage data for a targeted EZH1/EZH2 inhibitor and an immune-activating dual-antibody candidate address treatment gaps for patients with limited options. Existing 4-1BB-targeting antibodies have faced development halts over liver toxicity, making the reported absence of severe liver events a closely watched point.
The Phase 1 BH3120 monotherapy study enrolled 45 patients with advanced solid tumors, and no dose-limiting toxicities or severe Grade 3+ liver toxicity were reported across dose groups. Whether these early signals will hold in larger, later-stage trials remains unknown.
The players
Hanmi Pharmaceutical
Hanmi Pharmaceutical is a South Korean drugmaker that develops oncology and other therapeutics, including the PentamBody platform used to build BH3120.
The details
HM97662 simultaneously inhibits the EZH1 and EZH2 proteins and showed initial anti-tumor activity in patients with ovarian clear cell carcinoma and chordoma, with activity also confirmed in mesothelioma and uterine sarcoma. BH3120, built on Hanmi's PentamBody dual-antibody platform, binds PD-L1 on cancer cells and 4-1BB on immune cells to activate T-cells, and it showed initial anti-tumor activity across various solid tumors.
Timeline
October 23-27, 2026: ESMO Congress 2026 held in Madrid, Spain, where results were presented.
2025: Early clinical results for HM97662 were announced.
November 17, 2026: Hanmi announced the Phase 1 results.
Clinical Landscape
Earlier 4-1BB-targeting antibodies stalled in clinical development because of liver toxicity, and Hanmi's BH3120 is positioned to test whether tumor-restricted activation can avoid that problem. Its early Phase 1 safety data are therefore being read against that specific history.
For patients with advanced solid tumors and few remaining options, these early studies are the first step toward potential new treatments, though no approved therapy is available yet. Any future access will depend on larger trials confirming safety and benefit.
The takeaway
Early Phase 1 signals are encouraging but preliminary, and the key question is whether the favorable safety and initial anti-tumor activity hold up in larger, later-stage trials. Readers should treat these results as early-stage findings rather than evidence of an available treatment.
Further reading
Explore more on Cancer research and treatment developments.







